Eli Lilly Cash on Hand 2010-2023 | LLY

Eli Lilly cash on hand from 2010 to 2023. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
  • Eli Lilly cash on hand for the quarter ending December 31, 2023 was $2.928B, a 32.37% increase year-over-year.
  • Eli Lilly cash on hand for 2023 was $2.928B, a 32.37% increase from 2022.
  • Eli Lilly cash on hand for 2022 was $2.212B, a 43.41% decline from 2021.
  • Eli Lilly cash on hand for 2021 was $3.909B, a 6.17% increase from 2020.
Eli Lilly Annual Cash on Hand
(Millions of US $)
2023 $2,928
2022 $2,212
2021 $3,909
2020 $3,681
2019 $2,439
2018 $7,409
2017 $8,034
2016 $6,039
2015 $4,452
2014 $4,827
2013 $5,397
2012 $5,684
2011 $6,897
2010 $6,727
2009 $4,498
Eli Lilly Quarterly Cash on Hand
(Millions of US $)
2023-12-31 $2,928
2023-09-30 $2,494
2023-06-30 $2,829
2023-03-31 $3,669
2022-12-31 $2,212
2022-09-30 $2,742
2022-06-30 $2,737
2022-03-31 $2,568
2021-12-31 $3,909
2021-09-30 $3,825
2021-06-30 $3,271
2021-03-31 $3,051
2020-12-31 $3,681
2020-09-30 $3,630
2020-06-30 $2,388
2020-03-31 $1,777
2019-12-31 $2,439
2019-09-30 $1,653
2019-06-30 $2,368
2019-03-31 $2,137
2018-12-31 $7,409
2018-09-30 $9,036
2018-06-30 $6,910
2018-03-31 $4,790
2017-12-31 $8,034
2017-09-30 $6,943
2017-06-30 $5,434
2017-03-31 $3,506
2016-12-31 $6,039
2016-09-30 $4,227
2016-06-30 $3,935
2016-03-31 $2,995
2015-12-31 $4,452
2015-09-30 $4,319
2015-06-30 $4,231
2015-03-31 $4,140
2014-12-31 $4,827
2014-09-30 $4,810
2014-06-30 $5,127
2014-03-31 $5,212
2013-12-31 $5,397
2013-09-30 $5,379
2013-06-30 $4,711
2013-03-31 $4,732
2012-12-31 $5,684
2012-09-30 $6,900
2012-06-30 $5,262
2012-03-31 $4,925
2011-12-31 $6,897
2011-09-30 $6,784
2011-06-30 $6,330
2011-03-31 $6,713
2010-12-31 $6,727
2010-09-30 $6,140
2010-06-30 $5,197
2010-03-31 $4,758
2009-12-31 $4,498
2009-09-30 $3,929
2009-06-30 $3,490
2009-03-31 $3,508
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $721.736B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $562.737B 46.36
Johnson & Johnson (JNJ) United States $358.552B 14.27
Merck (MRK) United States $319.493B 84.10
AbbVie (ABBV) United States $296.619B 15.08
AstraZeneca (AZN) United Kingdom $215.324B 19.08
Novartis AG (NVS) Switzerland $199.963B 13.85
Pfizer (PFE) United States $149.151B 14.39
Sanofi (SNY) $117.880B 10.61
Innoviva (INVA) United States $0.930B 6.57